241 related articles for article (PubMed ID: 33799513)
1. New Therapeutic Opportunities for the Treatment of Squamous Cell Carcinomas: A Focus on Novel Driver Kinases.
Bensen R; Brognard J
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799513
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P; Gonzalez S
Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
[TBL] [Abstract][Full Text] [Related]
3. TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.
Torres-Ayuso P; An E; Nyswaner KM; Bensen RC; Ritt DA; Specht SI; Das S; Andresson T; Cachau RE; Liang RJ; Ries AL; Robinson CM; Difilippantonio S; Gouker B; Bassel L; Karim BO; Miller CJ; Turk BE; Morrison DK; Brognard J
Cancer Discov; 2021 Jun; 11(6):1411-1423. PubMed ID: 33495197
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck.
Clauditz TS; Böttcher A; Hanken H; Borgmann K; Sauter G; Wilczak W; Grob T; Münscher A
J Cancer Res Clin Oncol; 2018 Jan; 144(1):53-61. PubMed ID: 29022097
[TBL] [Abstract][Full Text] [Related]
6. Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma.
Liu Y; Yin N; Wang X; Khoor A; Sambandam V; Ghosh AB; Fields ZA; Murray NR; Justilien V; Fields AP
Cell Rep; 2020 Jan; 30(3):771-782.e6. PubMed ID: 31968252
[TBL] [Abstract][Full Text] [Related]
7. Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.
Cai Y; Dodhia S; Su GH
Oncotarget; 2017 Mar; 8(13):22203-22217. PubMed ID: 28108737
[TBL] [Abstract][Full Text] [Related]
8. Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma.
Yang YL; Chu JY; Luo ML; Wu YP; Zhang Y; Feng YB; Shi ZZ; Xu X; Han YL; Cai Y; Dong JT; Zhan QM; Wu M; Wang MR
Genes Chromosomes Cancer; 2008 Feb; 47(2):127-36. PubMed ID: 17990328
[TBL] [Abstract][Full Text] [Related]
9. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
[TBL] [Abstract][Full Text] [Related]
10. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
11. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
[TBL] [Abstract][Full Text] [Related]
12. EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.
Iida K; Nakayama K; Rahman MT; Rahman M; Ishikawa M; Katagiri A; Yeasmin S; Otsuki Y; Kobayashi H; Nakayama S; Miyazaki K
Br J Cancer; 2011 Jul; 105(3):420-7. PubMed ID: 21730982
[TBL] [Abstract][Full Text] [Related]
13. Amplification of the 3q26.3 locus is associated with progression to invasive cancer and is a negative prognostic factor in head and neck squamous cell carcinomas.
Singh B; Stoffel A; Gogineni S; Poluri A; Pfister DG; Shaha AR; Pathak A; Bosl G; Cordon-Cardo C; Shah JP; Rao PH
Am J Pathol; 2002 Aug; 161(2):365-71. PubMed ID: 12163360
[TBL] [Abstract][Full Text] [Related]
14. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Agochiya M; Brunton VG; Owens DW; Parkinson EK; Paraskeva C; Keith WN; Frame MC
Oncogene; 1999 Oct; 18(41):5646-53. PubMed ID: 10523844
[TBL] [Abstract][Full Text] [Related]
15. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
16. 3q26 Amplifications in Cervical Squamous Carcinomas.
Voutsadakis IA
Curr Oncol; 2021 Jul; 28(4):2868-2880. PubMed ID: 34436017
[TBL] [Abstract][Full Text] [Related]
17. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
18. A simple specific pattern of chromosomal aberrations at early stages of head and neck squamous cell carcinomas: PIK3CA but not p63 gene as a likely target of 3q26-qter gains.
Redon R; Muller D; Caulee K; Wanherdrick K; Abecassis J; du Manoir S
Cancer Res; 2001 May; 61(10):4122-9. PubMed ID: 11358835
[TBL] [Abstract][Full Text] [Related]
19. Copy number changes of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: TP63 is amplified in early carcinogenesis but down-regulated as disease progressed.
Yen CC; Chen YJ; Pan CC; Lu KH; Chen PC; Hsia JY; Chen JT; Wu YC; Hsu WH; Wang LS; Huang MH; Huang BS; Hu CP; Chen PM; Lin CH
World J Gastroenterol; 2005 Mar; 11(9):1267-72. PubMed ID: 15761962
[TBL] [Abstract][Full Text] [Related]
20. Loss of TACSTD2 contributed to squamous cell carcinoma progression through attenuating TAp63-dependent apoptosis.
Wang F; Liu X; Yang P; Guo L; Liu C; Li H; Long S; Shen Y; Wan H
Cell Death Dis; 2014 Mar; 5(3):e1133. PubMed ID: 24651436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
